The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESSO 43 | Debating the role of adjuvant HIPEC after cancer surgery
Ignace H.J.T. de Hingh, MD, PhD, Catharina Cancer Institute, Eindhoven, Netherlands, addresses the ongoing debate surrounding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) after cancer surgery to prevent peritoneal metastasis. While peritoneal metastasis significantly worsens both quality of life and survival, studies show mixed results. Given the procedure’s invasiveness and cost, HIPEC is not yet recommended in this setting, though better patient selection may offer future potential. This interview took place at the ESSO 43 congress in Antwerp, Belgium.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
